Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clozapine
Drug ID BADD_D00511
Description A tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.
Indications and Usage For use in patients with treatment-resistant schizophrenia.
Marketing Status Prescription; Discontinued
ATC Code N05AH02
DrugBank ID DB00363
KEGG ID D00283
MeSH ID D003024
PubChem ID 135398737
TTD Drug ID D0Z1RV
NDC Product Code 57664-345; 0904-7088; 16729-141; 71554-025; 0093-3086; 51079-921; 55154-3568; 60687-404; 0378-3815; 51407-086; 0093-3087; 52817-601; 76072-1010; 0378-0972; 60687-548; 51862-274; 60429-989; 64374-004; 70518-3391; 12828-0072; 0378-0825; 60687-415; 53296-0033; 65862-846; 57664-241; 55154-8285; 57664-347; 65015-706; 60429-990; 51862-901; 0378-3813; 51407-085; 63552-062; 63629-2360; 69809-0126; 60687-426; 63629-2361; 72721-1725; 72721-1760; 0093-4404; 0904-7089; 67835-0028; 65862-847; 16729-142; 0378-0860; 57664-211; 51862-903; 0093-7772; 51862-273; 65862-844; 51079-749; 51079-922; 0093-5377; 0904-7087; 63629-2362; 65862-845; 70518-3357; 63552-063; 0093-5416; 69809-0130; 72721-1750; 51079-288; 72721-1770; 0093-4359; 0093-5419; 69809-0127; 0093-5376; 69809-0135; 63629-2359; 0378-0973; 73377-150; 51862-902; 0093-5417; 0093-4405; 51862-900
Synonyms Clozapine | Clozaril | Leponex
Chemical Information
Molecular Formula C18H19ClN4
CAS Registry Number 5786-21-0
SMILES CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Tardive dyskinesiaD(4) dopamine receptorP21917T2498310821369; 10379516; 10893495; 9777180; 10889553
Tardive dyskinesiaD(2) dopamine receptorP14416T6716210821369; 10379516; 10893495; 9777180; 10889553
Tardive dyskinesiaD(3) dopamine receptorP35462T0255110821369; 10379516; 10893495; 9777180; 10889553
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Coma scale abnormal13.07.03.0120.030826%Not Available
Staphylococcus test positive13.08.01.0150.005605%Not Available
Hepatitis C virus test positive13.08.03.0240.014012%Not Available
Norovirus test positive13.08.03.0310.005605%Not Available
Huntington's disease17.01.01.005; 03.10.01.0090.010966%Not Available
False positive investigation result13.18.01.0070.005605%Not Available
Metabolic cardiomyopathy02.04.01.010; 14.11.01.0410.005605%Not Available
Systolic dysfunction02.04.02.0350.019617%Not Available
Foetal monitoring abnormal13.21.01.0070.008407%Not Available
N-terminal prohormone brain natriuretic peptide increased13.02.04.0120.008407%Not Available
Infectious pleural effusion22.05.01.004; 11.01.09.0110.008407%Not Available
Encephalitis autoimmune17.06.05.002; 16.32.01.006; 10.04.10.0120.008407%Not Available
Antipsychotic drug level decreased13.17.01.0290.246611%Not Available
Invasive ductal breast carcinoma21.05.01.021; 16.10.01.013--Not Available
Benign ethnic neutropenia01.02.03.0140.028024%Not Available
Internal haemorrhage24.07.01.072--Not Available
End stage renal disease20.01.03.019--Not Available
Intracranial mass17.11.01.0170.001462%Not Available
Obsessive-compulsive symptom19.06.05.0100.014012%Not Available
Selective eating disorder14.03.02.024; 19.09.01.0120.016814%Not Available
The 48th Page    First    Pre   48    Total 48 Pages